|
The Business Insider: The Money Game Eli Lilly jumps 10% after it says it will seek approval for its Alzheimer's drug following designation as a breakthrough therapy by the FDA
|
Goldman Sachs said Eli Lilly's decision to seek accelerated approval for donanemab was ahead of its expectations.
Full "The Business Insider: The Money Game" article
|
|